This study is looking at a drug called AFA-281 to see if it's safe and how well it works for people with alcohol use disorder (AUD). Researchers want to see if AFA-281 can help reduce alcohol cravings, change how people respond to alcohol, and affect things like pain, anxiety, depression, and sleep. You might be able to join if you are between 21 and 65 years old and have been diagnosed with moderate or severe AUD in the past year. The study is currently unclear about its recruitment status and plans to enroll 36 participants.

Study design

This is a randomized, double-blind, placebo-controlled study involving 36 participants. Participants will be assigned to receive either 60 mg of AFA-281, 120 mg of AFA-281, or a placebo (an inactive substance).

What's involved

The total study duration is about 42 days, including a 2-week screening period. Participants will start with a lower dose, increase it over 2 weeks, and then maintain that dose for another 2 weeks. In the fourth week, participants will have 7 daily visits for assessments and questionnaires.

Compensation

Not stated in the trial record.

Follow-up

Alcohol cravings and subjective response to alcohol will be measured weekly through Week 4. The overall study duration is approximately 42 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.